NASDAQ: HSDT
Solana Co Stock

$2.30-0.09 (-3.77%)
Updated May 15, 2026
HSDT Price
$2.30
Fair Value Price
N/A
Market Cap
$126.58M
52 Week Low
$1.59
52 Week High
$258.50
P/E
-1.24x
P/B
0.42x
P/S
10.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.02M
Earnings
-$40.89M
Gross Margin
91.7%
Operating Margin
-669.02%
Profit Margin
-679.6%
Debt to Equity
0.01
Operating Cash Flow
-$17M
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HSDT Overview

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HSDT's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
HSDT
Ranked
#66 of 95

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$10.58A
$35.68A
$22.74A
View Top Medical Device Stocks

Be the first to know about important HSDT news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HSDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HSDT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HSDT is good value based on its book value relative to its share price (0.42x), compared to the US Medical Devices industry average (2.92x)
P/B vs Industry Valuation
HSDT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HSDT due diligence checks available for Premium users.

Valuation

HSDT fair value

Fair Value of HSDT stock based on Discounted Cash Flow (DCF)

Price
$2.30
Fair Value
-$2.23
Undervalued by
203.20%
HSDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HSDT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.24x
Industry
22.36x
Market
22.65x

HSDT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.42x
Industry
2.92x
HSDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HSDT's financial health

Profit margin

Revenue
$5.2M
Net Income
$325.6M
Profit Margin
6,227.1%
HSDT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HSDT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$303.9M
Liabilities
$3.0M
Debt to equity
0.01
HSDT's short-term assets ($31.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSDT's short-term assets ($31.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSDT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HSDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.2M
Investing
-$159.1M
Financing
$48.6M
HSDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HSDT vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HSDTC$126.58M-3.77%-1.24x0.42x
QTRXC$129.54M-0.72%-1.18x0.46x
NNOXD$119.70M-2.82%-1.48x0.86x
RCELC$140.34M+4.59%-2.92x-6.06x
MXCTC$111.41M-4.59%-2.81x0.66x

Solana Co Stock FAQ

What is Solana Co's quote symbol?

(NASDAQ: HSDT) Solana Co trades on the NASDAQ under the ticker symbol HSDT. Solana Co stock quotes can also be displayed as NASDAQ: HSDT.

If you're new to stock investing, here's how to buy Solana Co stock.

What is the 52 week high and low for Solana Co (NASDAQ: HSDT)?

(NASDAQ: HSDT) Solana Co's 52-week high was $258.50, and its 52-week low was $1.59. It is currently -99.11% from its 52-week high and 44.65% from its 52-week low.

How much is Solana Co stock worth today?

(NASDAQ: HSDT) Solana Co currently has 55,034,047 outstanding shares. With Solana Co stock trading at $2.30 per share, the total value of Solana Co stock (market capitalization) is $126.58M.

Solana Co stock was originally listed at a price of $14,188,132.09 in Jun 27, 2014. If you had invested in Solana Co stock at $14,188,132.09, your return over the last 11 years would have been -100%, for an annualized return of -75.86% (not including any dividends or dividend reinvestments).

How much is Solana Co's stock price per share?

(NASDAQ: HSDT) Solana Co stock price per share is $2.30 today (as of May 15, 2026).

What is Solana Co's Market Cap?

(NASDAQ: HSDT) Solana Co's market cap is $126.58M, as of May 17, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Solana Co's market cap is calculated by multiplying HSDT's current stock price of $2.30 by HSDT's total outstanding shares of 55,034,047.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.